
Overview
Pharmaceutical company's Q2 revenue beat analyst expectations
Adjusted EBITDA for Q2 beat analyst expectations
Outlook
Company did not provide specific financial guidance for future quarters or full year in press release
Result Drivers
SHIFT IN MARKETING - Decreased net revenue from ADHD and Pediatric portfolios due to marketing focus shift to EXXUA
INVESTMENTS IN EXXUA - Significant investments in EXXUA launch impacted adjusted EBITDA, which still beat expectations
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $15.17 mln | $12.17 mln (3 Analysts) |
Q2 Net Income |
| -$10.58 mln |
|
Q2 Adjusted EBITDA | Beat | -$800,000 | -$4.30 mln (3 Analysts) |
Q2 Gross Profit |
| $9.62 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Aytu Biopharma Inc is $8.00, about 195.2% above its February 2 closing price of $2.71
Press Release: ID:nACStMvP3a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.